Advertisement
Advertisement

DSGN

DSGN logo

Design Therapeutics, Inc. Common Stock

10.19
USD
Sponsored
-0.38
-3.64%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

10.19

0.00
+0.05%

DSGN Earnings Reports

Positive Surprise Ratio

DSGN beat 12 of 19 last estimates.

63%

Next Report

Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.36
Implied change from Q3 25 (Revenue/ EPS)
--
/
+20.00%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+50.00%

Design Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, DSGN reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.35 USD, resulting in a 14.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an increase of 20.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Design Therapeutics, Inc. Common Stock reported EPS of -$0.30, beating estimates by 14.33%, and revenue of $0.00, 0% as expectations.
The stock price moved up 4.89%, changed from $6.55 before the earnings release to $6.87 the day after.
The next earning report is scheduled for Mar 09, 2026.
Based on 6 analysts, Design Therapeutics, Inc. Common Stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement